{"slug":"gynaecological","tag":"gynaecological","variants":["gynaecological"],"description":"No description yet","count":7,"kinds":{"person":7},"related":[{"slug":"trialist","tag":"trialist","shared":7},{"slug":"endometrial","tag":"endometrial","shared":4},{"slug":"immunotherapy","tag":"immunotherapy","shared":2},{"slug":"ovarian","tag":"ovarian","shared":2},{"slug":"cervical","tag":"cervical","shared":1},{"slug":"targeted-therapy","tag":"targeted-therapy","shared":1}],"records":[{"id":"krishnansu-tewari","kind":"person","name":"Krishnansu S. Tewari","route":"/people/krishnansu-tewari/","tldr":"California gynaecologic oncologist who led GOG 240, the trial that made bevacizumab the first targeted drug to lengthen survival in advanced cervical cancer, and EMPOWER-Cervical 1, which did the same for the PD-1 antibody cemiplimab."},{"id":"david-gershenson","kind":"person","name":"David M. Gershenson","route":"/people/david-gershenson/","tldr":"Houston gynaecologic oncologist who defined low-grade serous ovarian cancer as a distinct disease and led GOG 281, the trial that showed the MEK inhibitor trametinib works better than standard treatments for it."},{"id":"vicky-makker","kind":"person","name":"Vicky Makker","route":"/people/vicky-makker/","tldr":"New York oncologist who led KEYNOTE-775, the trial that established lenvatinib plus pembrolizumab for advanced endometrial cancer after chemotherapy."},{"id":"shannon-westin","kind":"person","name":"Shannon N. Westin","route":"/people/shannon-westin/","tldr":"Houston gynaecologic oncologist who led DUO-E, the trial that added durvalumab, with or without olaparib, to first-line chemotherapy for advanced endometrial cancer."},{"id":"ana-oaknin","kind":"person","name":"Ana Oaknin","route":"/people/ana-oaknin/","tldr":"Barcelona oncologist who led GARNET, the trial that brought dostarlimab to mismatch repair-deficient endometrial cancer, and who has led many trials of new drugs for gynaecological cancers."},{"id":"amanda-fader","kind":"person","name":"Amanda Nickles Fader","route":"/people/amanda-fader/","tldr":"Baltimore gynaecologic oncologist who led the trial showing that adding trastuzumab to chemotherapy helps women with HER2-positive uterine serous carcinoma, an aggressive form of endometrial cancer."},{"id":"susana-banerjee","kind":"person","name":"Susana Banerjee","route":"/people/susana-banerjee/","tldr":"London gynaecological oncologist who led RAMP 201, the trial that established the avutometinib and defactinib combination for recurrent KRAS-mutant low-grade serous ovarian cancer."}]}